Lung Cancer

Drs Chi, Peravali, and Jadhav discuss the practical advantages and clinical implications of implementing in-house NGS testing for patients with NSCLC.

The FDA priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.

Dr Sands discusses the rapidly evolving treatment landscape for SCLC.

Lyudmila A. Bazhenova, MD, discusses the evolving treatment landscape in ROS1-rearranged metastatic NSCLC.

CHMP recommended trastuzumab deruxtecan for HER2-positive (IHC 3+) metastatic solid tumors, marking the first tumor-agnostic ADC opinion in the EU.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

Sevabertinib has received priority review designation from the FDA in locally advanced or metastatic, HER2 TKD–mutant NSCLC.

OncLive announced the 2026 Giants of Cancer Care winners.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.

The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.

Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC.

An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC

Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the potential future utility of PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

The FDA cleared vepdegestrant in ER+ breast cancer with ESR1 mutations, ODAC voted on key questions in breast and prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Dr Cooper discusses recent advances that have reshaped the treatment paradigm for small cell lung cancer, particularly in the relapsed setting.

Jonathan Wennan Lee, MD, MSc; and Ashish Saxena, MD, PhD, discuss the future for evaluating PD-L1 expression as a biomarker in EGFR-mutated NSCLC.

The investigational pan-RAS inhibitor generated robust responses across 2 phase 1 dose-escalation studies that numerically exceeded historical benchmarks.

The regulatory agency has set a PDUFA action date of February 27, 2027, for zipalertinib in locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

Ris-rez plus adebrelimab led to an approximate 50% response rate and durable disease control in pretreated nonsquamous NSCLC without actionable mutations.